pharmaphorum
JANUARY 30, 2023
A spokesperson for the agency stated, “Shortages can have multiple causes, including manufacturing problems causing delays or interruption in the production, shortages of raw materials, increased demand of medicines, distribution problems, labour disruptions, and natural disasters.”
pharmaphorum
OCTOBER 11, 2022
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. Indeed, of the 281 WHO-listed essential medicines, 100% of respiratory treatments are Teva’s. The patient, he said, is the most important part of that.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 26, 2021
Taking part in a fireside chat at the recent virtual Reuters Events: Pharma 2021 meeting, he explained how the COVID-19 pandemic had been a “wakeup call” for the industry, and spoke about the strategies that could help build the European healthcare systems of the future.
European Pharmaceutical Review
FEBRUARY 2, 2023
This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions. Alarmingly, there are now 93 active ingredients for which no European company holds a certificate.
European Pharmaceutical Review
JULY 29, 2024
The Committee for Medicinal Products for Human Use (CHMP) has recommended against a marketing authorisation for Leqembi (lecanemab), as a treatment for Alzheimer’s disease, during its July meeting last week. Tuznue (trastuzumab) for breast and gastric cancer.
Hospital Pharmacy Europe
AUGUST 13, 2024
In 2022, the Executive Steering Group on Shortages and Safety of Medicinal Products was established to ensure a robust response to medicine supply issues caused by major events or public health emergencies. A number of initiatives have been implemented at a European level over the last few years.
Pharmaceutical Technology
DECEMBER 19, 2022
While the ripple effect of such an event is expected across sectors, in the pharmaceutical arena, small and mid-sized enterprises (SMEs) are predicted to be heavily impacted as the economic downturn affects plans to raise capital, amongst other things. million as part of the Build Back Better Regional Challenge.
Expert insights. Personalized for you.
104 
Let's personalize your content